Moreover, in a subset comparison of age and risk-matched COVID-19 patients with pre-existing T2D and poor glucose control (blood glucose >10.0 mmol/L), there was a reduction in mortality from 11.1% to 1.1% with significantly lower d-dimer, C-reactive protein (CRP) and interleukin 6 (IL6) when glucose was maintained in a range of 3.9-10 mmol/L (29). The gene discussed is IL6; the disease is COVID-19.